
Akari Therapeutics and Peak Bio announce merger
Biotechnology company Akari Therapeutics and biopharmaceutical company Peak Bio have announced a definitive agreement to merge as equals in an all-stock transaction. The combined entity will operate as Akari Therapeutics, which is expected to continue to be listed and trade on the Nasdaq Capital Market as AKTX. Following closing, the… Read More
